large cell carcinoma

Summary

Summary: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)

Top Publications

  1. Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun S, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer. 2006;53:285-94 pubmed
    ..These results suggest that, in addition to adenocarcinomas, acquired loss of function mutations in LKB1 may also be frequently involved in the pathogenesis of large cell lung carcinomas...
  2. Tsai W, Yu J, Lin C, Hsieh C. Primary alveolar-type large cell neuroendocrine carcinoma of the breast. Breast J. 2005;11:487 pubmed
  3. Su C, Yang J, Lu C, Chiang J, Wu C, Lin J, et al. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res. 2010;24:189-92 pubmed publisher
    ..The findings indicate that curcumin can inhibit tumour growth in a NCI-H460 xenograft animal model in vivo...
  4. Hasegawa S, Suda T, Negi K, Hattori Y. Lung large cell carcinoma producing granulocyte-colony-stimulating factor. Ann Thorac Surg. 2007;83:308-10 pubmed
    ..We experience a case of lung carcinoma producing granulocyte-colony-stimulating factor treated by resection and chemotherapy. He remains well 2 years and 10 months after surgery, with no recurrence of the carcinoma...
  5. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, De Jong D, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18:99-103 pubmed
    ..Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs...
  6. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-78 pubmed
    ..Tumor uptake of [(18)F]FMT was compared with that of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression...
  7. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46-52 pubmed publisher
    ..The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer...
  8. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, et al. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori. 2008;94:398-405 pubmed
  9. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006;125:860-5 pubmed
    ..EGFR protein expression was uncoupled from gene amplification in most cases, although good correlation occurred in a subset of SCCs...
  10. Pardo J, Martinez Peñuela A, Sola J, Panizo A, Gurpide A, Martínez Peñuela J, et al. Large cell carcinoma of the lung: an endangered species?. Appl Immunohistochem Mol Morphol. 2009;17:383-92 pubmed publisher

Detail Information

Publications99

  1. Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun S, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer. 2006;53:285-94 pubmed
    ..These results suggest that, in addition to adenocarcinomas, acquired loss of function mutations in LKB1 may also be frequently involved in the pathogenesis of large cell lung carcinomas...
  2. Tsai W, Yu J, Lin C, Hsieh C. Primary alveolar-type large cell neuroendocrine carcinoma of the breast. Breast J. 2005;11:487 pubmed
  3. Su C, Yang J, Lu C, Chiang J, Wu C, Lin J, et al. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res. 2010;24:189-92 pubmed publisher
    ..The findings indicate that curcumin can inhibit tumour growth in a NCI-H460 xenograft animal model in vivo...
  4. Hasegawa S, Suda T, Negi K, Hattori Y. Lung large cell carcinoma producing granulocyte-colony-stimulating factor. Ann Thorac Surg. 2007;83:308-10 pubmed
    ..We experience a case of lung carcinoma producing granulocyte-colony-stimulating factor treated by resection and chemotherapy. He remains well 2 years and 10 months after surgery, with no recurrence of the carcinoma...
  5. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, De Jong D, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18:99-103 pubmed
    ..Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs...
  6. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-78 pubmed
    ..Tumor uptake of [(18)F]FMT was compared with that of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression...
  7. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46-52 pubmed publisher
    ..The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer...
  8. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, et al. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori. 2008;94:398-405 pubmed
  9. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006;125:860-5 pubmed
    ..EGFR protein expression was uncoupled from gene amplification in most cases, although good correlation occurred in a subset of SCCs...
  10. Pardo J, Martinez Peñuela A, Sola J, Panizo A, Gurpide A, Martínez Peñuela J, et al. Large cell carcinoma of the lung: an endangered species?. Appl Immunohistochem Mol Morphol. 2009;17:383-92 pubmed publisher
  11. Wang C, Lin K, Yang C, Tsai J, Hung J, Wang P, et al. Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. Kaohsiung J Med Sci. 2010;26:68-75 pubmed
    ..Its safety has also been confirmed in animal studies. However, its anti-cancer properties in human lung large cell carcinoma have not been studied...
  12. Harada M, Yokose T, Yoshida J, Nishiwaki Y, Nagai K. Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung. Lung Cancer. 2002;38:177-84 pubmed
    The clinical significance of neuroendocrine (NE) differentiation is unclear in large cell carcinoma (LCC) of the lung...
  13. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Baba M, Fujisawa T, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer. 2001;92:1108-12 pubmed
    In 1999, the World Health Organization categorized large cell neuroendocrine carcinoma, large cell carcinoma with neuroendocrine differentiation, and large cell carcinoma with neuroendocrine morphology as a variant of large cell carcinoma...
  14. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res. 2002;93:15-23 pubmed
    ..The possibility of one group changing to resemble another and of groups converging in the near future is suggested...
  15. Yoshii T, Muraoka S, Sano N, Furudoi S, Komori T. Large cell carcinoma of the lung metastatic to the mandibular gingiva. J Periodontol. 2002;73:571-4 pubmed
    ..Although metastases of malignant tumors to the jaws are not unusual, metastases to the gingival soft tissues are relatively rare...
  16. Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer. Anticancer Drugs. 2002;13:505-9 pubmed
    ..The response rate and survival data in this phase I study are encouraging. We considered that the pathogenesis of diarrhea involved not only direct cytotoxic damage to the mucosa, but also bacterial overgrowth...
  17. Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami Chouaib F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci U S A. 2002;99:9358-63 pubmed
    We have previously identified an antigen (Ag) recognized on a human large cell carcinoma of the lung by a tumor-specific cytotoxic T lymphocyte clone derived from autologous tumor infiltrating lymphocytes (TILs)...
  18. Jakopovic M, Slobodnjak Z, Krizanac S, Samarzija M. Large cell carcinoma arising in bronchogenic cyst. J Thorac Cardiovasc Surg. 2005;130:610-2 pubmed
  19. Yoshimi I, Ohshima A, Ajiki W, Tsukuma H, Sobue T. A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. Jpn J Clin Oncol. 2003;33:98-104 pubmed
    ..For large cell carcinoma, the decreasing trend began earlier in the SEER...
  20. Jemal A, Travis W, Tarone R, Travis L, Devesa S. Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type. Int J Cancer. 2003;105:101-7 pubmed
    ..incidence rates for white men and women converged rapidly for adenocarcinoma, small cell carcinoma, and large cell carcinoma, but less so for squamous cell carcinoma...
  21. Iyoda A, Baba M, Hiroshima K, Saitoh H, Moriya Y, Shibuya K, et al. Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: Comparison with classic large cell carcinoma. Oncol Rep. 2004;11:285-8 pubmed
    The World Health Organization (WHO) categorized large cell neuroendocrine carcinoma (LCNEC) as a variant of large cell carcinoma in 1999. However, cytologic features of these tumors have not yet been adequately characterized...
  22. Krivak T, McBroom J, Sundborg M, Crothers B, Parker M. Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature. Gynecol Oncol. 2001;82:187-91 pubmed
    ..These tumors appear to mimic the aggressive behavior of small cell neuroendocrine tumors. Metastasis and recurrent disease are common. Due to the low incidence of these tumors, optimal therapy has not been delineated...
  23. Choi Y, Han C, Kim J, Oh I, Lee J, Nam J, et al. Effectiveness of sputum cytology using ThinPrep method for evaluation of lung cancer. Diagn Cytopathol. 2008;36:167-71 pubmed publisher
    ..6% (TP) and 69.4% (CP). Sputum cytology using the TP method improves the diagnostic accuracy for evaluating lung cancer by reducing the unsatisfactory and false-negative rates. ..
  24. Ma K, Liu Y, Xue Z, Chu X. Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: A single center experience of 41 patients. Medicine (Baltimore). 2017;96:e7842 pubmed publisher
    ..The surgical treatment of NETTs, CgA negative, and low grade of NETTs were associated with a statistically significant better prognosis. However, large, multicenter studies are required to fully validate these prognostic factors...
  25. Edkins S, O Meara S, Parker A, Stevens C, Reis M, Jones S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006;5:928-32 pubmed
  26. Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009;4:1544-9 pubmed publisher
    ..33-0.67, p = 0.001). Patients with advanced NSCLC may benefit from third-line treatment. The best candidates can be identified using standard prognostic factors, such as PS, and disease control after first- and second-line treatments. ..
  27. Simon E, Howells M, Stuart J, Boehme K. Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus. Viruses. 2017;9: pubmed publisher
    ..We found that rsT1L was markedly more cytolytic than rsT3D in the large cell carcinoma cell lines tested, whereas killing of adenocarcinoma cell lines was comparable between rsT1L and rsT3D...
  28. Kayser G. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. Pathologe. 2015;36 Suppl 2:189-93 pubmed publisher
    ..cell carcinoma, large cell neuroendocrine carcinoma (LCNEC) and NSCLC not otherwise specified (NOS) large cell carcinoma, as required by the new World Health Organization (WHO) classification of 2015, on a single glass slide...
  29. Lee J, Han J, Lee D, Kim H, Chun J, Lee H, et al. A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:761-7 pubmed
    ..The TX regimen showed modest antitumor effects in patients with previously treated NSCLC. For further studies, we recommend T 30 mg/m(2) i.v. on days 1 and 8 plus X 625 mg/m(2) p.o. b.i.d. on days 1-14 of a 21-day cycle. ..
  30. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22:709-17 pubmed publisher
  31. Truong T, Hung R, Amos C, Wu X, Bickeböller H, Rosenberger A, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst. 2010;102:959-71 pubmed publisher
    ..Future genetic studies of lung cancer should include detailed stratification by histology. ..
  32. Copin M. [Large cell carcinoma, lymphoepithelioma-like carcinoma, NUT carcinoma]. Ann Pathol. 2016;36:24-33 pubmed publisher
    The diagnosis of large cell carcinoma can only be made on a sampled resected tumor and should not be applied to biopsies or cytology...
  33. Stankovic M, Nestorovic A, Tomovic A, Petrovic Stanojevic N, Andjelic Jelic M, Dopudja Pantic V, et al. TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Neoplasma. 2009;56:348-52 pubmed
    ..Although these results need to be confirmed on larger cohort, they represent anew and interesting finding, not reported in other populations tested so far. ..
  34. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4:5-11 pubmed publisher
    ..About 5% of pulmonary adenocarcinomas in this cohort of Japanese patients were driven by activated MET by gene amplification or splice mutations. Such patients would be candidates for targeted therapy against MET. ..
  35. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006;19:1358-68 pubmed
    ..biological features of small cell carcinoma (n=23), large cell neuroendocrine carcinoma (n=17), and classic large cell carcinoma (n=12)...
  36. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol. 2010;5:1120-9 pubmed publisher
    ..This study reveals apelin as a novel angiogenic factor in human NSCLC. Moreover, it also provides the first evidence for a direct association of apelin expression with clinical outcome in a human cancer. ..
  37. Leinonen T, Pirinen R, Böhm J, Johansson R, Kosma V. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol. 2008;23:693-700 pubmed publisher
    ..017, p=0.001 and p=0.021, p=0.008, respectively). The present study shows the significant prognostic value of MMP-2 in NSCLC suggesting that the use of MMP-2 is valuable in determining the patients with more aggressive disease. ..
  38. Krypuy M, Newnham G, Thomas D, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295 pubmed
    ..HRM will enable high-throughput screening of gene mutations to allow appropriate therapeutic choices for patients and accelerate research aimed at identifying novel mutations in human cancer. ..
  39. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska Gulida G, et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer. 2006;52:9-14 pubmed
    ..Additionally, the correlation between Pro72 and somatic TP53 mutations suggests that Pro72 allele carriers may be predisposed to tumour development along a p53 associated form of NSCLC, a finding that warrants further investigations. ..
  40. Noguchi M, Suzuki T, Kabayama K, Takahashi H, Chiba H, Shiratori M, et al. GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Sci. 2007;98:1625-32 pubmed
  41. Sterlacci W, Saker S, Huber B, Fiegl M, Tzankov A. Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. Virchows Arch. 2016;468:463-71 pubmed publisher
    ..be an independent prognostic parameter for the entire cohort and for patients with adenocarcinoma (ACA) and large cell carcinoma (LCC)...
  42. Goh B, Yeo A, Koong H, Ooi L, Wong W. Laparotomy for acute complications of gastrointestinal metastases from lung cancer: is it a worthwhile or futile effort?. Surg Today. 2007;37:370-4 pubmed
    ..range, 0-8 months) and the histological subtypes of the lung cancer were squamous cell carcinoma (n = 3), large cell carcinoma (n = 3), adenocarcinoma (n = 1), pleomorphic carcinoma (n = 1) and pleomorphic with adenocarcinoma (n = 1)...
  43. Strazisar M, Mlakar V, Glavac D. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol Lett. 2009;14:442-56 pubmed publisher
    ..Our study shows differences in the expression patterns within the NSCLC group, which may mimic the expression of the individual NSCLC type, and also new relationships in the expression levels for different NSCLC types. ..
  44. Wang D, Zeng C, Lin Y, Hou J, Zhu Z. [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer]. Ai Zheng. 2006;25:359-62 pubmed
    ..52+/-9) months, P<0.05]. Apoptosis-related oncogenes may have some impacts on the occurrence and development of stage I-II NSCLC. TNM stage and positive expression of Survivin are independent prognostic factors. ..
  45. Fukuda M, Soda H, Fukuda M, Kinoshita A, Nakamura Y, Nagashima S, et al. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. Cancer. 2007;110:606-13 pubmed
    ..1/33.4 months, respectively. This combined modality of irinotecan and cisplatin with concurrent TRT is active and further investigations are warranted at the second group dose level. ..
  46. Wahbah M, Boroumand N, Castro C, El Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11:89-96 pubmed
    ..In addition, there are significant changes in the distribution of the major histologic types of lung cancer. The results of this study may portend important changes in the selection of targeted therapy and patient management...
  47. Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, et al. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2007;37:482-6 pubmed
    ..The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear...
  48. Dhillon T, Mauri F, Bellezza G, Cagini L, Barbareschi M, North B, et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010;5:314-9 pubmed publisher
    ..Here, we investigate whether the immunohistochemical expression of a key kinase implicated in lung cancer biology, the mammalian target of rapamycin (mTOR) can predict survival outcome in patients with early stage resected NSCLC...
  49. Beleford D, Liu Z, Rattan R, Quagliuolo L, Boccellino M, Baldi A, et al. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res. 2010;16:398-409 pubmed publisher
    ..Some 85% of lung cancers are smoking related. Here, we investigate the role of serine protease HtrA3 in smoking-related lung cancer...
  50. Shimakage M, Kodama K, Kawahara K, Kim C, Ikeda Y, Yutsudo M, et al. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors. Oncol Rep. 2009;21:1367-72 pubmed
    ..Our results indicate that the downregulation of drs is correlated with the development of SCLC, a highly malignant pulmonary neuroendocrine tumor...
  51. Hirsh V, Soulieres D, Duclos M, Faria S, del Vecchio P, Ofiara L, et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol. 2007;2:927-32 pubmed
    ..The role of induction chemotherapy with carboplatin/gemcitabine regimen has not been established in stage III NSCLC...
  52. Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol. 2010;25:1257-67 pubmed publisher
    ..In lung carcinomas dysadherin expression seems to reflect tumour aggressiveness and may be considered a positive marker of poor prognosis when considered alone or/and in combination with down-regulation of E-cadherin...
  53. Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007;2:916-26 pubmed
    ..On the basis on the results, a phase II study using a regimen of four fractions during 1 week was performed. The purpose of the present study was to determine the local control and 5-year survival rates...
  54. Gollard R, Jhatakia S, Elliott M, Kosty M. Large cell/neuroendocrine carcinoma. Lung Cancer. 2010;69:13-8 pubmed publisher
    ..We review treatment data, and suggest that as in more common types of lung cancer, multi-modality therapy may be the most promising course of treatment...
  55. Chae M, Jang J, Kang H, Park J, Park J, Lee W, et al. O6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer. Mol Carcinog. 2006;45:239-49 pubmed
  56. Sugaya M, Takenoyama M, Shigematsu Y, Baba T, Fukuyama T, Nagata Y, et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer. 2007;120:1055-62 pubmed
    ..study was to elucidate the tumor-specific cellular immunological responses occurring in a patient with large cell carcinoma of the lung who had no evidence of recurrence following surgical resections of both a primary lung lesion ..
  57. Ou S, Zell J. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4:1202-11 pubmed publisher
    ..We investigated whether the distribution of carcinoma NOS (not otherwise specified) among NSCLC cases in California have changed over time and determined the prognostic significance of carcinoma NOS...
  58. Uchida N, Fukino S, Kodama W, Tamai N, Hiroe T, Fukata T. Large-cell carcinoma of the lung with a remarkable preoperative elevation of serum carcinoembryonic antigen level. Gen Thorac Cardiovasc Surg. 2007;55:217-21 pubmed
    ..This is a rare case of lung cancer with no evidence of recurrence and metastasis for 8 years despite markedly elevated preoperative carcinoembryonic antigen levels...
  59. Nakatsugawa M, Hirohashi Y, Torigoe T, Asanuma H, Takahashi A, Inoda S, et al. Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4. Cancer Sci. 2009;100:1485-93 pubmed publisher
    ..Hence, Lengsin splicing variant 4 might be an immunogenic lung cancer-specific antigen that is suitable as a diagnostic marker and for molecular targeting therapy, including immunotherapy...
  60. van der Vliet H, Lefesvre P, van Groeningen C. [A patient with very high serum level of human chorionic gonadotrophin; the diagnosis is not always a germ-cell tumour]. Ned Tijdschr Geneeskd. 2008;152:705-9 pubmed
    ..Using this patient's history, ectopic HCG production by malignancies is described in more detail...
  61. Sergiacomi G, Schillaci O, Leporace M, Laviani F, Carlani M, Manni C, et al. Integrated multislice CT and Tc-99m Sestamibi SPECT-CT evaluation of solitary pulmonary nodules. Radiol Med. 2006;111:213-24 pubmed
    ..Scintigraphy was performed using a 'hybrid' g-camera that allows simultaneous acquisition of SPECT and CT images, with interesting results in diagnostic oncology...
  62. Hsu C, Kuo S, Hu F, Cheng A, Shih J, Yu C, et al. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Lung Cancer. 2008;62:334-43 pubmed publisher
  63. Varlotto J, Recht A, Nikolov M, Flickinger J, Decamp M. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer. 2009;115:851-8 pubmed publisher
    ..It is uncertain whether lymphadenectomy (LA) affects overall survival (OS) or disease-free survival (DFS) rates for patients with stage I nonsmall cell lung cancer (NSCLC), as is the optimal number of lymph nodes that should be recovered...
  64. Chang G, Liu K, Hsieh C, Hu T, Charoenfuprasert S, Liu H, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res. 2006;12:5746-54 pubmed
    ..In this study, we intended to identify more TAAs in pleural effusion-derived tumor cells...
  65. Lindboe C. Large cell neuroendocrine carcinoma of the ovary. APMIS. 2007;115:169-76 pubmed
    ..She developed bleomycin-induced lung fibrosis that responded well to treatment with steroids. There have been no signs of local tumour recurrence or metastases at follow-up examinations during the first 9 months after the operation...
  66. Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan C, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971-8 pubmed publisher
    ..This large, prospectively-recruited patient cohort has previously been analyzed based on differences in FDG uptake across stage groups; the current analysis adds further dimensions to this characterization...
  67. Nakas C, Alonzo T. ROC graphs for assessing the ability of a diagnostic marker to detect three disease classes with an umbrella ordering. Biometrics. 2007;63:603-9 pubmed
    ..methods are illustrated using data from a study assessing the ability of a DNA methylation marker to correctly classify lung specimens into three histologic classes: squamous cell carcinoma, large cell carcinoma, and nontumor lung.
  68. Sakamoto J, Sekine T. [Pulmonary pleomorphic carcinoma with rapid and peculiar metastases; report of a case]. Kyobu Geka. 2007;60:253-7 pubmed
    ..He was diagnosed as large cell carcinoma by transbronchial biopsy. Preoperative chemotherapy and right lower lobectomy were done...
  69. Maeshima A, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H. Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J Thorac Oncol. 2010;5:466-71 pubmed publisher
    ..Clarification of the clinicopathologic characteristics of patients with multiple atypical adenomatous hyperplasias (AAHs)...
  70. Park J, Yang H, Kim H, Kim K, Shim Y, Choi Y, et al. Sleeve lobectomy as an alternative procedure to pneumonectomy for non-small cell lung cancer. J Thorac Oncol. 2010;5:517-20 pubmed publisher
    ..The aim of this study is to compare the outcomes of sleeve lobectomy (SL) and pneumonectomy (PN) and to determine which one is more acceptable standard procedure for patients with non-small cell lung cancer...
  71. Lu Y, Xie D, Huang W, Gong H, Yu J. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Neoplasma. 2010;57:129-34 pubmed
    ..It allows early detection and accurate localization of adrenal lesions and differentiation of metastatic nodules from benign lesions, thereby facilitating treatment planning...
  72. Hjelde H, Sundstrøm S, Ødegård A, Hatlinghus S, Abusland A, Haaverstad R. [Recurrence and survival after surgical treatment of lung cancer]. Tidsskr Nor Laegeforen. 2010;130:25-8 pubmed publisher
    ..The aim of the study was to review survival and recurrence, and factors which affect survival, in patients operated for lung cancer...
  73. Hanagiri T, Sugio K, Uramoto H, Sugaya M, Ono K, So T, et al. Results of surgical treatment for lung cancer in young adults. Int Surg. 2008;93:50-4 pubmed
    ..There were no significant differences in survival rates between younger group and elderly groups. This study suggests that surgical resection is also recommended as the first-line treatment for younger patients with lung cancer...
  74. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 2009;125:2393-9 pubmed publisher
    ..609 vs. 3.192 months, p = 0.006). These results suggest that the blood-based EGFR mutations test has the ability to provide a reliable guidance for clinical decision making for the treatment of the advanced NSCLC patients...
  75. Lee H, Lee H, Kim Y, Kang C, Jang B, Chung D, et al. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2010;5:497-503 pubmed publisher
  76. Moreira A, Gonen M, Rekhtman N, Downey R. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol. 2010;23:889-95 pubmed publisher
    ..material of resected untreated pulmonary carcinomas, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell carcinoma...
  77. Gao L, Zhu W, Feng Z, An N. [Comparative proteomic analysis of human large cell lung cancer cell line with high and low metastasis potentials]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008;39:706-10 pubmed
    ..A comparative proteomic analysis on two human large cell lung cancer strains with high metastasis potential (L9981) and low metastasis potential (NL9980) were conducted...
  78. Suemitsu R, Ueda H, Shikada Y, Ondo K, Yoshino I, Maehara Y. Relationship of tumor size to survival in patients with pT2N0 lung cancer. Asian Cardiovasc Thorac Ann. 2006;14:30-4 pubmed
    ..4%, 47.9%, and 21.9% in each group, respectively. In the two subgroups with tumor sizes 3-4 cm and > 4 cm, the 5-year survival was 63.8% and 48.1%, respectively. Tumors > 4 cm in diameter indicate a poor long-term prognosis...
  79. Zhu X, Guo Y, Li X, Ding Y, Chen L. Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J Thorac Oncol. 2010;5:1159-66 pubmed publisher
    ..Little research has been done to test the usefulness of metastasis-associated protein 1 (MTA1) as a prognostic marker for non-small cell lung cancer (NSCLC). In this study, we investigated MTA1 expression and its prognostic value for NSCLC...
  80. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol. 2007;2:902-6 pubmed
    ..We sought to determine the influence of ERCC1 mRNA expression in advanced NSCLC on chemotherapy response, toxicity, and survival after platinum-based chemotherapy...
  81. Stern P, Bartos V, Uhrova J, Bezdickova D, Vanickova Z, Tichy V, et al. Performance characteristics of seven neuron-specific enolase assays. Tumour Biol. 2007;28:84-92 pubmed
    ..The individual results of different immunoassays are often not comparable, which has been confirmed by long-term external quality assessments. In this study, we assessed the possible sources of these differences...
  82. Hillion J, Wood L, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009;7:1803-12 pubmed publisher
    ..Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors...
  83. Fernandez F, Battafarano R. Large-cell neuroendocrine carcinoma of the lung: an aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg. 2006;18:206-10 pubmed
    ..This article reviews the tumor characterization, biology, presentation and diagnosis, surgical therapy, results of therapy, and long term prognosis of patients with LCNEC...
  84. Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, et al. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn J Clin Oncol. 2006;36:477-82 pubmed
    ..To assess the pharmacokinetic profile and time-course of trough concentrations and hemoglobin levels associated with subcutaneous weekly administration of epoetin beta in lung cancer patients with chemotherapy-induced anemia...
  85. Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, et al. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol. 2010;5:49-55 pubmed publisher
    ..The purpose of this study was to assess a novel histopathological evaluation method for predicting the outcome of NSCLC treated by neoadjuvant therapy...